Cargando…

P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells

Cervical cancer is the third most commonly diagnosed cancer worldwide and the fourth leading cause of cancer-related mortality in females worldwide, accounting for 10–15% of cancer-related mortalities. Cytological screening and DNA testing for high-risk human papillomavirus (HPV) types have markedly...

Descripción completa

Detalles Bibliográficos
Autores principales: LI, YUERAN, XIAO, SONGSHU, DAN, LIU, XUE, MIN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315085/
https://www.ncbi.nlm.nih.gov/pubmed/25663864
http://dx.doi.org/10.3892/ol.2014.2814
_version_ 1782355425616723968
author LI, YUERAN
XIAO, SONGSHU
DAN, LIU
XUE, MIN
author_facet LI, YUERAN
XIAO, SONGSHU
DAN, LIU
XUE, MIN
author_sort LI, YUERAN
collection PubMed
description Cervical cancer is the third most commonly diagnosed cancer worldwide and the fourth leading cause of cancer-related mortality in females worldwide, accounting for 10–15% of cancer-related mortalities. Cytological screening and DNA testing for high-risk human papillomavirus (HPV) types have markedly decreased the rates of cervical cancer in developed countries, however, for vulnerable populations without access to health care, cervical cancer remains a considerable problem. Chemotherapeutic agents such as cisplatin (DDP) are considered as first-line treatment for cervical carcinoma. Although initially patients often exhibit high responsiveness, the majority eventually develop DDP resistance. However, the mechanisms underlying this process remain unclear. Furthermore, patients with metastatic cancer and those exhibiting persistent or recurrent disease after platinum-based chemoradiotherapy have limited options and thus, non-platinum combination chemotherapy has been proposed as a strategy to circumvent platinum resistance, however, novel therapeutic strategies are required. In the present study, P16 expression was analyzed by quantitative-polymerase chain reaction and western blot analysis in SiHa and SiHa-DDP cells and the interaction between P16 and CDK4 was detected via co-immunoprecipitation. In addition, the proliferation and apoptosis rates of P16 knockdown SiHa-DDP cells were measured by MTT assay and Annexin V flow cytometry and the subsequent changes in cyclin D1 and pRb expression were analyzed by western blot analysis. In this study, a high level of P16(INK4A) expression and its enhanced interaction with cyclin-dependent kinase-4 in cervical carcinoma DDP-resistance cells (SiHa-DDP) was identified, which was associated with the inactivation of phosphorylated retinoblastoma protein (pRb). Knockdown of P16(INK4A) significantly induced cellular growth, when compared with the control cells, via the upregulation of pRb, and also promoted apoptosis following treatment with DDP. The results of this study indicated, for the first time, that P16(INK4A) is required for DDP resistance in cervical carcinoma SiHa cells and, thus, these results may lead to the development of novel strategies for the treatment of chemoresistant cervical carcinoma.
format Online
Article
Text
id pubmed-4315085
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-43150852015-02-06 P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells LI, YUERAN XIAO, SONGSHU DAN, LIU XUE, MIN Oncol Lett Articles Cervical cancer is the third most commonly diagnosed cancer worldwide and the fourth leading cause of cancer-related mortality in females worldwide, accounting for 10–15% of cancer-related mortalities. Cytological screening and DNA testing for high-risk human papillomavirus (HPV) types have markedly decreased the rates of cervical cancer in developed countries, however, for vulnerable populations without access to health care, cervical cancer remains a considerable problem. Chemotherapeutic agents such as cisplatin (DDP) are considered as first-line treatment for cervical carcinoma. Although initially patients often exhibit high responsiveness, the majority eventually develop DDP resistance. However, the mechanisms underlying this process remain unclear. Furthermore, patients with metastatic cancer and those exhibiting persistent or recurrent disease after platinum-based chemoradiotherapy have limited options and thus, non-platinum combination chemotherapy has been proposed as a strategy to circumvent platinum resistance, however, novel therapeutic strategies are required. In the present study, P16 expression was analyzed by quantitative-polymerase chain reaction and western blot analysis in SiHa and SiHa-DDP cells and the interaction between P16 and CDK4 was detected via co-immunoprecipitation. In addition, the proliferation and apoptosis rates of P16 knockdown SiHa-DDP cells were measured by MTT assay and Annexin V flow cytometry and the subsequent changes in cyclin D1 and pRb expression were analyzed by western blot analysis. In this study, a high level of P16(INK4A) expression and its enhanced interaction with cyclin-dependent kinase-4 in cervical carcinoma DDP-resistance cells (SiHa-DDP) was identified, which was associated with the inactivation of phosphorylated retinoblastoma protein (pRb). Knockdown of P16(INK4A) significantly induced cellular growth, when compared with the control cells, via the upregulation of pRb, and also promoted apoptosis following treatment with DDP. The results of this study indicated, for the first time, that P16(INK4A) is required for DDP resistance in cervical carcinoma SiHa cells and, thus, these results may lead to the development of novel strategies for the treatment of chemoresistant cervical carcinoma. D.A. Spandidos 2015-03 2014-12-19 /pmc/articles/PMC4315085/ /pubmed/25663864 http://dx.doi.org/10.3892/ol.2014.2814 Text en Copyright © 2015, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
LI, YUERAN
XIAO, SONGSHU
DAN, LIU
XUE, MIN
P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells
title P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells
title_full P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells
title_fullStr P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells
title_full_unstemmed P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells
title_short P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells
title_sort p16(ink4a) is required for cisplatin resistance in cervical carcinoma siha cells
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315085/
https://www.ncbi.nlm.nih.gov/pubmed/25663864
http://dx.doi.org/10.3892/ol.2014.2814
work_keys_str_mv AT liyueran p16ink4aisrequiredforcisplatinresistanceincervicalcarcinomasihacells
AT xiaosongshu p16ink4aisrequiredforcisplatinresistanceincervicalcarcinomasihacells
AT danliu p16ink4aisrequiredforcisplatinresistanceincervicalcarcinomasihacells
AT xuemin p16ink4aisrequiredforcisplatinresistanceincervicalcarcinomasihacells